Anti-nucleosome B Lymphocytes in Lupus

University Hospital, Strasbourg, France

Status: Terminated

Conditions: Systemic Lupus Erythematosus With or Without Clinical Activity

Treatments: Other: Venous blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT01889654

5543

Details and patient eligibility

About

Lupus disease is characterized by the production of pathogenic autoantibodies, which participate in end-organ damages. The phenotype of B cells producing the pathogenic autoantibodies in lupus patients is today unknown. Antinucleosome antibodies are characteristic of lupus disease.This project proposes to detect antinucleosome B cells in lupus patients and to analyse their phenotype and their frequency.

Enrollment: 4 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria for SLE patients:

SLE patient : diagnostic based on ACR criteria

• SLE patient producing seric anti-nucleosome antibodies (ELISA)
• SLEDAI-2K activity score : inferior to 5 for quiescent patients, superior to 8 since at least 2 months for active patients

Exclusion criteria for SLE patients:

-- Other autoimmune diseases than SLE- Induced lupus

• Treatment with corticosteroids >10mg/d (prednisone) for quiescent patients
• Treatment with corticosteroids >20mg/d (prednisone) for active patients
• Oral immunosuppressive treatment during the last 6 months (methotrexate, azathioprine, ciclosporine, mycophénolate mofétil) for all patients, treatment during the last year with cyclophosphamide or monoclonal antibodies (rituximab, belimumab) for pour quiescent patients
• Disease which can modify B and T lymphocyte functions: primary immune deficiencies, evolutive infections, chronic viral infection (VIH in particular), chemotherapy or neoplasm antecedent

Trial design

4 participants in 2 patient groups

patient

Treatment:

Other: Venous blood sampling

healthy volunteers

Treatment:

Other: Venous blood sampling